The Evolving Landscape of TGCT Treatment: Merck's Pimicotinib and the Competitive CSF-1R Inhibitor Market

Merck KGaA, a leading science and technology company, is poised to significantly impact the treatment landscape for tenosynovial giant cell tumors (TGCT) with its recent filing for global regulatory approvals of pimicotinib. This selective colony stimulating factor 1 receptor (CSF-1R) inhibitor has demonstrated promising results in the Phase III MANEUVER trial